History & Mission
Creating a community where no one affected by Alzheimer’s and dementia makes the journey alone.
Our Story
The Bridge Alzheimer’s & Dementia Resource Center, formerly The Alzheimer’s Agency of Shreveport/Bossier, Inc., is a nonprofit organization that received 501(c)(3) status in 2007. It was founded by a coalition of individuals whose lives had been deeply touched by Alzheimer’s disease and other dementias. Recognizing the lack of local resources, education, and support, these founding members set out to create a place where families could turn for guidance, information, and hope.
Today, The Bridge serves nine parishes across Northwest Louisiana, offering a wide range of programs and services designed to support individuals living with dementia and their caregivers. Our team includes Care Navigators to guide families through every stage of the journey and a Licensed Professional Counselor who provides one-on-one and family counseling.
We provide:
- Caregiver support groups facilitated throughout the community
- Monthly education workshops on dementia care and related topics
- Memory screenings and early detection resources
- Engaging activities for caregivers and loved ones living with dementia
- Printed and online resource directories to connect families with local services
- Assistance with legal and planning matters
In addition, our Speaker’s Bureau offers education and training for civic groups, healthcare providers, law enforcement, faith-based organizations, and other community partners.
At The Bridge, we are committed to helping families maintain dignity, strengthen relationships, and find encouragement while navigating the challenges of Alzheimer’s disease and dementia.
OUR MISSION
The mission of The Bridge Alzheimer’s & Dementia Resource Center is to provide resources, education, and support services for those in our community diagnosed with Alzheimer’s disease and related dementias, as well as to their family members and caregivers, and to promote awareness in our community.
New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
